BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
The steroid-free, long-acting anticholinergic gains another selling point as others ready drugs for the $7 billion to $8 billion COPD market.
You may also be interested in...
Almirall Signs Up Forest For Once-Daily LABA
Forest pays $75 million up front for U.S. rights to Almirall's once-daily long-acting beta agonist in combination with a corticosteroid.
Safety Meta-Analysis Trumped By Long, Large Trial At Spiriva Advisory Panel
A clinical trial trumps a meta-analysis for assessing drug safety, at least when it's large and well-done - that was the message from FDA's Pulmonary-Allergy Drugs Advisory Committee during its review of an additional indication for Boehringer Ingelheim's Spiriva HandiHaler Nov. 19
BI's Spiriva Gets Advisory Panel Nod For COPD Exacerbations Despite Statistical Issues
Committee finds clinical trial safety results more compelling than meta-analysis, and is undeterred by the lack of statistical significance in the study's primary endpoints.